Recursion Pharmaceuticals (NASDAQ:RXRX) Hits New 52-Week Low – What’s Next?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) hit a new 52-week low during trading on Wednesday . The stock traded as low as $3.77 and last traded at $3.7380, with a volume of 18343906 shares. The stock had previously closed at $4.10.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on RXRX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, January 22nd. UBS Group set a $11.00 price objective on Recursion Pharmaceuticals in a report on Wednesday, December 17th. Morgan Stanley set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 17th. Finally, JPMorgan Chase & Co. raised shares of Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price target for the company from $10.00 to $11.00 in a research note on Wednesday, December 17th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $9.40.

Recursion Pharmaceuticals Stock Performance

The company has a quick ratio of 4.60, a current ratio of 4.60 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $4.49 and a 200 day moving average price of $4.97. The stock has a market cap of $2.03 billion, a P/E ratio of -2.17 and a beta of 0.95.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.02. Recursion Pharmaceuticals had a negative return on equity of 72.74% and a negative net margin of 1,637.81%.The company had revenue of $5.18 million during the quarter, compared to analysts’ expectations of $19.36 million. During the same quarter in the previous year, the business earned ($0.34) EPS. Recursion Pharmaceuticals’s revenue was down 80.1% compared to the same quarter last year. As a group, sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Activity at Recursion Pharmaceuticals

In other news, insider Najat Khan sold 124,403 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $4.41, for a total transaction of $548,617.23. Following the completion of the sale, the insider owned 611,135 shares of the company’s stock, valued at approximately $2,695,105.35. The trade was a 16.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Blake Borgeson sold 220,000 shares of the stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $4.36, for a total value of $959,200.00. Following the completion of the transaction, the director directly owned 6,649,863 shares in the company, valued at approximately $28,993,402.68. This trade represents a 3.20% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 585,786 shares of company stock worth $2,558,598 in the last 90 days. 8.43% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several institutional investors have recently made changes to their positions in RXRX. Vanguard Group Inc. lifted its stake in shares of Recursion Pharmaceuticals by 18.6% during the 4th quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock worth $192,998,000 after purchasing an additional 7,407,606 shares during the last quarter. Norges Bank bought a new position in Recursion Pharmaceuticals in the second quarter worth about $16,040,000. Bank Pictet & Cie Europe AG purchased a new stake in shares of Recursion Pharmaceuticals during the third quarter valued at about $7,954,000. Geode Capital Management LLC boosted its holdings in shares of Recursion Pharmaceuticals by 20.7% in the 2nd quarter. Geode Capital Management LLC now owns 7,776,408 shares of the company’s stock valued at $39,353,000 after buying an additional 1,332,428 shares in the last quarter. Finally, Two Sigma Investments LP lifted its position in Recursion Pharmaceuticals by 109.9% during the third quarter. Two Sigma Investments LP now owns 2,450,805 shares of the company’s stock valued at $11,960,000 after acquiring an additional 1,282,992 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.